Insulet (PODD) AGM 2026 summary

Opening remarks and agenda

• CEO welcomed participants, introduced board members, and outlined meeting procedures and agenda.

• Independent auditors from PricewaterhouseCoopers were present to answer questions.

• Meeting materials, proxy statement, and annual report were made available online.

Financial performance review

• Achieved over $2.7 billion in revenue for 2025, marking a decade of 20%+ annual revenue growth.

• Growth driven by Omnipod 5 adoption and strong global customer retention.

• Expanded leadership in both Type 1 and Type 2 diabetes markets, with international growth highlighted.

• Manufacturing investments, including a Malaysia facility, improved capacity and margins.

Board and executive committee updates

• Three director nominees (Dr. Luciana Borio, Mike Minogue, Tim Stonesifer) were up for election for three-year terms.